NeoStem agrees to expand manufacturing services deal with Kite Pharma

May 5, 2015

Biopharmaceutical company NeoStem, Inc. has entered into a new cell therapy manufacturing agreement with Kite Pharma, Inc., a clinical-stage biopharmaceutical company that is developing engineered autologous T cell therapy (eACT) products for cancer treatment.

Biopharmaceutical company NeoStem, Inc. has entered into a new cell therapy manufacturing agreement with Kite Pharma, Inc., a clinical-stage biopharmaceutical company that is developing engineered autologous T cell therapy (eACT) products for cancer treatment.

Under an earlier agreement, NeoStem's subsidiary PCT and its center of excellence for cell therapy process development, engineering and manufacturing, provided development and manufacturing services for Kite's lead eACT clinical development program. These services included technology transfer, process development, qualification and implementation of the manufacturing process.

Through the expanded services agreement announced on April 20, PCT will dedicate more facilities and personnel to provide these services at its Mountain View, California, site.

"We look forward to continuing our mutually beneficial partnership with Kite and to offering manufacturing service for the important cell therapy that they plan to advance toward the commercial market," commented Dr. Robert A. Preti, chief scientific officer of NeoStem and president of PCT. "The expansion of NeoStem's arrangement with Kite allows us to grow our Mountain View facility and to continue providing innovative, reliable and high quality manufacturing expertise to cell therapy developers who are researching potentially life-changing treatments for patients across many therapeutic areas."

Dr. David J. Mazzo, NeoStem's CEO, also welcomed the new agreement and said that it would serve as a model for future collaborations between PCT and its clients.

Sponsored Recommendations

2024 Manufacturing Trends — Unpacking AI, Workforce, and Cybersecurity

The world of manufacturing is changing, and Generative AI is one of the many change agents. The 2024 State of Smart Manufacturing Report takes a deep dive into how Generative ...

State of Smart Manufacturing Report Series

The world of manufacturing is changing, and Generative AI is one of the many change agents. The 2024 State of Smart Manufacturing Report takes a deep dive into how Generative ...

Trying to Keep Pace with Supply Chain Disruption?

CPG manufacturers are struggling to keep up with supply chain disruptions. Learn how to build more resilient operations –and reduce demand shock.

Mitigating Cybersecurity Threats – Step-by-Step

Distributor Wesco adds services focused on identifying and solving OT network and security vulnerabilities in critical manufacturing.